EPRX — EUPRAXIA PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1581178 ·
Last close
$7.53
Market Cap
$491.91M
52W High
$8.52
52W Low
$6.26
ADV30
211,078
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,957,045 | -12,653,431 | 145,353,342 | 58,500,024 | 9,165,681 |
| Dec 2025 | 0 | — | -16,162,620 | -16,711,252 | 86,150,008 | 80,563,482 | 5,703,915 |
| Sep 2025 | 0 | — | -6,883,100 | -6,361,367 | 92,349,055 | 88,959,281 | 3,905,493 |
| Jun 2025 | 0 | — | -8,264,099 | -8,740,916 | 23,595,934 | 19,765,644 | 2,618,381 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,552,218
Investing CF
$-588,947
Financing CF
$76,058,540
CapEx
$-588,947
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-169,579,974
Inventory
—
Receivables
$674,226
ST Investments
—
EBIT TTM
$-38,586,561
Pretax Income TTM
$-38,586,561
Interest Exp TTM
$0
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,434,039 | -38,576,143 | 86,150,008 | 5,703,915 | — | -28,552,218 |
| Dec 2024 | 0 | -27,003,411 | -25,502,536 | 34,942,355 | 3,103,386 | — | -29,994,491 |
| Dec 2023 | 0 | -27,847,229 | -28,220,796 | 20,266,229 | 19,373,903 | — | -20,748,619 |
| Dec 2022 | 0 | -17,617,452 | -18,489,629 | 19,122,249 | 11,914,395 | — | -14,395,201 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.92
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | $474.43M | $4.16 | — |
| AQST | Aquestive Therapeutics, Inc. | $511.84M | $4.08 | — |
| EBS | Emergent BioSolutions Inc. | $471.07M | $9.13 | — |
| STTK | Shattuck Labs, Inc. | $468.52M | $6.11 | — |
| XOMA | XOMA Royalty Corp | $523.21M | $41.72 | — |
News headlines (Yahoo Finance, 1h cache)
Eupraxia Pharmaceuticals Q1 Loss Narrows
2026-05-12 21:21 · Yahoo
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-12 21:00 · Yahoo
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
2026-05-06 11:00 · Yahoo
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
2026-05-05 11:00 · Yahoo
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
2026-05-01 21:05 · Yahoo
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
2026-04-22 11:00 · Yahoo
Eupraxia Reports Latest 36-Week Results From Resolve Trial
2026-04-21 11:32 · Yahoo
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
2026-04-21 11:00 · Yahoo
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
2026-04-13 12:00 · Yahoo
New Strong Sell Stocks for April 2nd
2026-04-02 10:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.